Histopathological findings in 91 Ugandan patients with cirrhosis were studied in relation to serological tests for the hepatitis-associated antigen (H.A.A.) and antibody (anti-H.A.A.). H.A.A. was present in 30 (32.9%) of the 91 patients as opposed to 7 (3.1%) out of 224 controls drawn from the same population (P<0.001). Younger subjects and males were more frequently positive. There was no difference in the presence of anti-H.A.A. between patients and controls. Correlation of the results of serological testing with histopathological features showed that macronodular ("posthepatitic," "postnecrotic") types of cirrhosis, which predominate in Uganda, were associated with the presence of H.A.A. but that the much less common micronodular ("nutritional," fatty, portal) type of cirrhosis was not. Evidence was found, on the other hand, for a direct role of alcoholism in the latter. Detailed histological analysis also showed two types of cellular change-liver cell swelling and dysplasia-to be associated with the presence of H.A.A. The data suggest an aetiological role for H.A.A. in most cases of cirrhosis in Uganda and these may be identified by histological criteria.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1787362 | PMC |
http://dx.doi.org/10.1136/bmj.1.5797.403 | DOI Listing |
Emerg Microbes Infect
January 2025
Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia.
Hepatitis B virus (HBV) DNA integration into the host cell genome is reportedly a major cause of liver cancer, and a source of hepatitis B surface antigen (HBsAg). High HBsAg levels can alter immune responses which therefore contributes to the progression of HBV-related disease. However, to what extent integration leads to the persistent circulating HBsAg is unclear.
View Article and Find Full Text PDFWorld J Hepatol
December 2024
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan.
Background: A new nomenclature of metabolic associated steatotic liver disease (MASLD) was proposed in 2023, thus expanding the diagnostic name of "MASLD combined with other etiologies".
Aim: To investigate the clinical profiles of patients with concurrent MASLD and chronic hepatitis B virus (HBV) infection.
Methods: This study included participants from the Taiwan Bio-bank.
World J Gastroenterol
December 2024
Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China.
Background: Hepatocellular carcinoma (HCC) is a major factor for cancer-associated mortality globally. Although the systemic immune-inflammation index (SII) and albumin (ALB) show individual prognostic value for various cancers, their combined significance (SII/ALB) in HCC patients undergoing curative hepatectomy is still unknown. It is hypothesized that a higher SII/ALB ratio correlates with poorer outcomes with regard to overall survival (OS) and recurrence-free survival (RFS).
View Article and Find Full Text PDFLancet Reg Health Eur
February 2025
Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
Background: The health of the marginalized populations is crucial for public health and inequalities. The World Health Organization (WHO) Global Hepatitis Report 2024 stated that over 304 million people were living with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) infection in 2022. We performed HBV/HCV screenings among marginalized communities to reveal hidden infections and link-to-care positive participants.
View Article and Find Full Text PDFSci Rep
December 2024
Department of Gastroenterology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, Fujian, China.
Immune checkpoint inhibitor (ICI) therapy is the new standard treatment for advanced or metastatic hepatocellular carcinoma (HCC); however, many patients still fail to respond. This study explored the expression and prognosis of programmed death ligand 1 (PD-L1), cluster of differentiation 24 (CD24), and cluster of differentiation 47 (CD47) in patients with hepatitis B virus-associated HCC (HBV-associated HCC). We analyzed sequencing data from the Cancer Genome Atlas (TCGA) and investigated the expression of PD-L1, CD24, and CD47 in HBV-associated HCC patients by immunohistochemistry and their relationship with prognosis and clinicopathological factors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!